Killing HIV-infected cells by transduction with an HIV protease- activated caspase-3 protein

Nature Medicine

Volumn 5, Issue 1, 1999, Pages 29-33

  Vocero Akbani, Adita M ^a   Heyden, Nancy Vander ^a   Lissy, Natalie A ^a   Lee, Ratner ^a   Dowody, Steven F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; PROTEINASE;

ARTICLE; ENZYME ACTIVITY; GENE TARGETING; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; VIRUS INHIBITION;

CASPASE 3; CASPASES; ENZYME ACTIVATION; HIV PROTEASE; HIV-1; HUMANS; JURKAT CELLS; RECOMBINANT FUSION PROTEINS;

EID: 0033013888     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/4710     Document Type: Article

References (32)

1. Lillehoj, E.P. et al. Purification and structural characterization of the putative gagpol protease of human immunodeficiency virus. J. Virol. 62, 3053-3058 (1988).
2. Kohl, N.E. et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85, 4686-4690 (1988).
3. Göttlinger, H.G., Sodroski, J.G. & Haseltine, W.A. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86, 5781-5785 (1989).
4. Kaplan, A.H. et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA 91, 5597-5601 (1994).
5. Gatlin, J., Arrigo, S.J. & Schmidt, MG. Regulation of intracellular human immunodeficiency virus type-1 protease activity. Virology 244, 87-96 (1998).
6. Coffin, J.M., Hughes, S.H. & Varmus, H.E. Retroviruses (Cold Spring Harbor Press, Cold Spring Harbor, New York, 1997).
7. Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571 (1995).
8. Gulnik, S.V. et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34, 9282-9287 (1995).
9. Tisdale, M. et al. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimcrob. Agents Chemother. 39, 1704-1710 (1995).
10. Salvesen, G.S. & Dixit, V.M. caspases: intracellular signaling by proteolysis. Cell 91, 443-446 (1997).
11. Henkart, P.A. ICE family proteases: mediators of all apoptotic cell death? Immunity 4, 195-201 (1996).
12. Cohen, G.M. caspases: the executioners of apoptosis. J. Biochem. 326, 1-16 (1997).
13. Woo, M. et al. Essential contribution of caspase 3/Casp3 to apoptosis and its associated nuclear changes. Genes Dev. 12, 806-819 (1998).
14. Enari, M. et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391, 43-50 (1998).
15. Liu, X. et al. DFF40 induces DNA fragmentation and chromatin condensation during apoptosis. Proc. Natl. Acad. Sci. USA 15, 8461-8466 (1998).
16. Ratner, L. et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313, 277-284 (1985).
17. Rice, C.M. in Fields Virology (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 931-960 (Lippincott-Raven, Philadelphia, 1996).
18. Welch, A.R., Woods, A.S., McNally, L.M., Cotter, R.J. & Gibson, W. A. Herpesvirus maturational protease, assemblin: identification of its gene, putative active site domain, and cleavage site. Proc. Natl. Acad. Sci. USA 88, 10792-10796 (1991).
19. Francis, S.E., Sullivan, D.J. Jr. & Goldberg, D.E. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu. Rev. Microbiol. 51, 97-123 (1997).
20. Barrie, K.A. et al. Natural variation in HIV-1 protease, gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology 219, 407-416 (1996).
21. Ezhevsky, S.A. et al. Hypo-phosphorylation of the retinoblastoma protein by cyclin D:Cdk4/6 complexes results in active pRb. Proc. Natl. Acad. Sci. USA 94, 10699-10704 (1997).
22. 1 phase cell cycle check point. Immunity 8, 57-65 (1998).
23. kp1 mediates cell migration. Nature Med. 4, 1449-1452 (1998).
24. Vocero-Akbani, A. et al. Transduction of full length TAT fusion proteins directly into mammalian cells:analysis of TCR-activation induced cell death (AID) in Methods in Enzymology(ed. Reed, J.C.) (Academic, San Diego, in the press).
25. Coates, P.J. Molecular methods for the identification of apoptosis in tissues. J. Histotechnol. 17, 261-267 (1994).
26. Xiang, J., Chao, D.T. & Korsmeyer, S.J. Bax-induced cell death may not require interleukin 1B-converting enzyme-like proteases. Proc. Natl. Acad. Sci. USA 93, 14559-14563 (1996).
27. Westervelt, P., Genedelman, H.E. & Ratner, L. Identification of a determinant within the HIV-1 surface envelope glycoprotein critical for productive infection of cultured primary monocytes. Proc. Natl. Acad. Sci USA 88, 3097-3101 (1991).
28. Lou, X., Budihardjo, I., Zou, H., Slaughter, C. & Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-490 (1998).
29. Li, H., Zhu, C.-j. & Yuan, J. Cleavage of BID by caspase 8 mediates the mitochonrial damage in Fas pathway of apoptosis. Cell 95, 491-501 (1998).
30. Wong, J.K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
31. Finzi, D. et al. Identification of a reservior for HIV-1 patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
32. Wu, X. et al. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J. 16, 5113-5122 (1997).